Ingenza, a world-leading contract research, development and manufacturing organisation (CRDMO) and technology accelerator, has signed a 10-year lease at the Moubray Building at Edinburgh Technopole, part of Pioneer Group.
Following a detailed strategic review, the company has embarked on the creation of a multi-million-pound facility to help drive its ambitious growth plans. The purpose-built premises will more than double the company’s current footprint to approximately 25,000 sq ft, expanding its fermentation and research facilities.
Edinburgh Technopole is one of twelve life science…
London, October 3, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with MTIP and the Nitinotes Board to conduct a successful search for a new Chief Executive Officer (“CEO”) for Nitinotes. We are pleased to announce the placement of Lloyd Diamond in this key leadership role.Nitinotes is a pioneer in medical technology and a leader in Innovative Obesity Treatment. The Company developed EndoZip™, a minimally invasive, fully automated endoscopic suturing system aimed at treating…
Cancer Research UK, one of the world’s largest funders of cancer research, and NovalGen, a pioneering clinical stage immunology company, have signed an agreement to bring NovalGen’s next-generation T-cell engager, NVG-222, into a first-in-human clinical trial.
Under the agreement, Cancer Research UK’s Centre for Drug Development (CDD) will sponsor, design and deliver a Phase 1/2a clinical trial of NVG-222. NovalGen will be responsible for completing the Clinical Trial Authorisation (CTA)-enabling activities. Cancer Research Horizons, Cancer Research UK’s innovation arm, will manage the…
📖 Read October's eNews here 👉 https://shorturl.at/CUF5kFeaturing:✅ Tony Jones, CEO, One Nucleus: Engaging Our Members and Their Peers✅ Navigate Your Opportunities with Ease - Introducing the New Look One Nucleus Website ✅ How Can You Stay One Step Ahead in the Ever More Competitive Drug Discovery Space? by Domainex ✅ What Makes Transfer Pricing an Important Issue for Growing Life Sciences Businesses? by RSM✅ Celebrating Success: Putting Your Business in the Spotlight ✅ Are You a Bio-Innovation Trend Setter? Join the ON Helix Review✅ Equity Investment Into Spinouts 2024 by…
Amsterdam, the Netherlands and Sydney, Australia 30 September 2024 - Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, announces a collaboration with CMRI, a leading Australian pediatric medical research institute, and Omico, an organization uniting over 50 world-class cancer institutes in Australia and New Zealand.
The collaboration has been established to advance the understanding of the prevalence of alternative lengthening of telomeres (ALT) across tumor types and the genetic factors involved, and thereby accelerate the…
HAMBURG, GERMANY - A new study led by precision oncology pioneers Indivumed Therapeutics reveals significant changes in the molecular characteristics of tumor samples within as little as 10 minutes after surgical removal. The findings underline the importance of rapid snap freezing of tissue samples to reliably capture cancer biology and reveal novel drug targets.
Publishing in Cell Death & Disease, the study analyzed the impact of cold ischemia time (the time it takes to preserve surgically removed tissue) on more than 1,800 tumor and matched normal tissue samples across four cancer…
• Programmable, tunable, stable and specific gene silencing has been demonstrated across multiple target genes and multiple cell types
• PoC achieved with concomitant silencing of more than one gene
• Industrialisation of platform processes delivering significant increase in throughput
• Strategic in-house focus on development of pipeline of programmable advanced therapies in oncology and genetic disease
• Potential additional application to multiple high impact therapeutic areas through partnering including, hypoimmunogenicity/type 1 diabetes, inflammatory diseases and fibrosis
Stevenage,…
London, September 26, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with CellCentric and is pleased to announce the placement of Andy Fergus as Chief Development Officer. Andy joined CellCentric in September 2024, and is Boston based.CellCentric’s mission is to transform outcomes for people living with specific cancers, notably relapsed refractory multiple myeloma, as quickly and effectively as possible. The clinical-stage biotech company focuses on the development of inobrodib,…
PACE (Pathways to Antimicrobial Clinical Efficacy) has today launched its second funding round with up to £5 million available to support cutting-edge diagnostic projects. This funding is part of a broader £30 million investment to address the global challenge of antimicrobial resistance (AMR).
PACE is one of the UK’s largest public-private initiatives targeting early-stage antimicrobial drug and diagnostic discovery. The pioneering partnership between LifeArc, Medicines Discovery Catapult (MDC) and Innovate UK is driving the development of new tests and treatments to tackle deadly AMR, which…